Form 8-K - Current report:
SEC Accession No. 0001104659-23-072250
Filing Date
2023-06-16
Accepted
2023-06-16 16:17:53
Documents
13
Period of Report
2023-06-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2318997d1_8k.htm   iXBRL 8-K 40827
2 EXHIBIT 3.1 tm2318997d1_ex3-1.htm EX-3.1 7551
  Complete submission text file 0001104659-23-072250.txt   229798

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20230616.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20230616_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20230616_pre.xml EX-101.PRE 22599
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2318997d1_8k_htm.xml XML 3820
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 231021387
SIC: 2834 Pharmaceutical Preparations